Chicago—Women with hormone receptor–positive (HR-positive), HER2-negative breast cancer who are at a midrange risk by genomic scoring can forgo adjuvant chemotherapy without increasing their risk for recurrence, according to findings from a major trial.
In the study, called TAILORx, endocrine therapy was noninferior to chemoendocrine therapy in this population when outcomes were compared after nine years, according to investigator Joseph A. Sparano, MD, an associate